Abstract
To assess whether TGF-β isoforms are significantly increased after intravenous immunoglobulin (IVIG) infusion in the plasma of patients with multiple sclerosis (MS), 19 patients with clinically definite MS were enrolled in a double blind placebo controlled IVIG study. TGF-β1, TGF-β2, TGF-β3 plasma concentrations were measured prior and directly after IVIG infusions by specific ELISA. Compared to the placebo group, we found a significant increase in the plasma levels of all three TGF-β isoforms in patients treated with IVIG. The significantly increased TGF-β plasma concentrations in treated patients suggest an additional, immediate mechanism of action that may accompany the molecular effects of IVIG therapy in MS. The variable amount of the potent anti-inflammatory TGF-β isoforms within the IVIG preparations may exert a differentiated view regarding the manifold indications of IVIG therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
